Clinical progress note: Respiratory syncytial virus

IF 1.8 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

Journal of hospital medicine Pub Date : 2026-06-02 Epub Date: 2025-10-12 DOI:10.1002/jhm.70206

Justin B. Searns MD, Sean T. O'Leary MD

引用次数: 0

Abstract

Globally, respiratory syncytial virus (RSV) is responsible for more than 3.6 million hospitalizations and 100,000 deaths every year. Since 2023, three immunizations have been approved for clinical use, each targeting a different patient population. These newly available RSV immunizations are poised to prevent hospitalizations, reduce costs for healthcare systems, and save lives. This review will discuss the evidence behind these immunization strategies and examine their potential to blunt the global impact from RSV.

查看原文本刊更多论文

临床进展记录：呼吸道合胞病毒。

在全球范围内，呼吸道合胞病毒（RSV）每年导致360多万人住院，10万人死亡。自2023年以来，已经批准了三种免疫接种用于临床，每种免疫接种针对不同的患者群体。这些新获得的呼吸道合胞病毒免疫接种有望预防住院，降低卫生保健系统的成本，并挽救生命。本综述将讨论这些免疫策略背后的证据，并检查它们减弱RSV全球影响的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of hospital medicine 医学-医学：内科

CiteScore

4.40

自引率

11.50%

发文量

233

审稿时长

4-8 weeks

期刊介绍： JHM is a peer-reviewed publication of the Society of Hospital Medicine and is published 12 times per year. JHM publishes manuscripts that address the care of hospitalized adults or children. Broad areas of interest include (1) Treatments for common inpatient conditions; (2) Approaches to improving perioperative care; (3) Improving care for hospitalized patients with geriatric or pediatric vulnerabilities (such as mobility problems, or those with complex longitudinal care); (4) Evaluation of innovative healthcare delivery or educational models; (5) Approaches to improving the quality, safety, and value of healthcare across the acute- and postacute-continuum of care; and (6) Evaluation of policy and payment changes that affect hospital and postacute care.